You are here
Integrated Biotherapeutics, Inc.
UEI: XNTHMSN2JJP5
# of Employees: 30
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
Amount: $1,861,259.00PROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola ...
STTRPhase II2017Department of Health and Human Services National Institutes of Health -
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
Amount: $594,931.00Project Summary The Gram positive bacterium Bacillus anthracis is a very strong candidate for potential bioweaponizationand believed to have actually been weaponized by the former Soviet UnionAnthrax ...
STTRPhase I2017Department of Health and Human Services National Institutes of Health -
Structure-guided redesign of monoclonal antibodies targeting conserved filovirus epitopes
Amount: $284,365.00Project Summary The Filoviridae family consists of multiple phylogenetically diverse species including five species of ebolavirus and a single marburgvirus species with Marburg and Ravn viruses While ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
Amount: $229,991.00DESCRIPTION provided by applicant The ebolaviruses and Marburg virus MARV constitute the family Filoviridae andquot filovirusesandquot that cause severe hemorrhagic fever with human case fata ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
Infection Site Targeted Antitoxin Antibody (ISTAb) against Clostridium difficile
Amount: $230,063.00DESCRIPTION provided by applicant Exotoxins produced by a wide range of bacterial pathogens are known to play a key role in host pathogen interactions establishment of the infection and subversi ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus
Amount: $599,996.00DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening seps ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Immunotherapeutics to prevent HCV reinfection
Amount: $600,000.00DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, l ...
STTRPhase I2013Department of Health and Human Services National Institutes of Health -
Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies
Amount: $550,414.00DESCRIPTION (provided by applicant): Filoviruses, Ebola (EBOV) and Marburg (MARV), are causative agents of sever hemorrhagic fever in humans with case-fatality rates exceeding 88%. Filoviruses, design ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
A novel Structure Based Vaccine for staphylococcal alpha hemolysin
Amount: $590,778.00DESCRIPTION (provided by applicant): Staphylococcus aureus is a gram positive human pathogen that causes a wide range of infections ranging from skin and soft tissue infections to life threatening dis ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides
Amount: $593,316.00DESCRIPTION (provided by applicant): Staphylococcus aureus is a human pathogen that causes a wide range of diseases from skin and soft tissue infections (SSTI) to life threatening sepsis and pneumoni ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health
